These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16787335)

  • 1. N-terminal anthranoyl-phenylalanine derivatives as CCK1 receptor antagonists: the final approach.
    Varnavas A; Lassiani L; Valenta V; Ciogli A; Gasparrini F; Mennuni L; Makovec F
    Med Chem; 2005 Sep; 1(5):501-17. PubMed ID: 16787335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthranilic acid based CCK1 receptor antagonists: preliminary investigation on their second "touch point".
    Varnavas A; Lassiani L; Valenta V; Mennuni L; Makovec F; Hadjipavlou-Litina D
    Eur J Med Chem; 2005 Jun; 40(6):563-81. PubMed ID: 15922840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R).
    Pavan MV; Lassiani L; Berti F; Stefancich G; Ciogli A; Gasparrini F; Mennuni L; Ferrari F; Escrieut C; Marco E; Makovec F; Fourmy D; Varnavas A
    J Med Chem; 2011 Aug; 54(16):5769-85. PubMed ID: 21728335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthranilic acid based CCK1 antagonists: the 2-indole moiety may represent a "needle" according to the recent homonymous concept.
    Varnavas A; Lassiani L; Valenta V; Berti F; Tontini A; Mennuni L; Makovec F
    Eur J Med Chem; 2004 Jan; 39(1):85-97. PubMed ID: 14987837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their "receptor desmodynamic processes".
    De Luca S; Saviano M; Lassiani L; Yannakopoulou K; Stefanidou P; Aloj L; Morelli G; Varnavas A
    J Med Chem; 2006 Apr; 49(8):2456-62. PubMed ID: 16610788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand.
    Lassiani L; Pavan MV; Berti F; Kokotos G; Markidis T; Mennuni L; Makovec F; Varnavas A
    Bioorg Med Chem; 2009 Mar; 17(6):2336-50. PubMed ID: 19261479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-terminal anthranoyl-anthranilic acid derivatives and their evaluation on CCK receptors.
    Varnavas A; Lassiani L; Luxich E; Valenta V
    Farmaco; 2000 Apr; 55(4):293-302. PubMed ID: 10966161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthranilic acid derivatives: a new class of non-peptide CCK1 receptor antagonists.
    Varnavas A; Lassiani L; Valenta V; Berti F; Mennuni L; Makovec F
    Bioorg Med Chem; 2003 Mar; 11(5):741-51. PubMed ID: 12538004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of new anthranilic acid dimer derivatives and their evaluation on CCK receptors.
    Varnavas A; Lassiani L; Valenta V
    Farmaco; 2000 May; 55(5):369-75. PubMed ID: 10983282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2D-QSAR and 3D-QSAR/CoMFA analyses of the N-terminal substituted anthranilic acid based CCK(1) receptor antagonists: 'Hic Rhodus, hic saltus'.
    Hadjipavlou-Litina D; Braiuca P; Lassiani L; Pavan MV; Varnavas A
    Bioorg Med Chem; 2009 Jul; 17(14):5198-206. PubMed ID: 19523833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of N-terminal substituted anthranilic acid dimer derivatives for evaluation on CCK receptors.
    Varnavas A; Valenta V; Berti F; Lassiani L
    Farmaco; 2001 Aug; 56(8):555-64. PubMed ID: 11601640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series.
    Pippel M; Allison BD; Phuong VK; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6373-5. PubMed ID: 19811913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
    Allison BD; Phuong VK; McAtee LC; Rosen M; Morton M; Prendergast C; Barrett T; Lagaud G; Freedman J; Li L; Wu X; Venkatesan H; Pippel M; Woods C; Rizzolio MC; Hack M; Hoey K; Deng X; King C; Shankley NP; Rabinowitz MH
    J Med Chem; 2006 Oct; 49(21):6371-90. PubMed ID: 17034143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformationally constrained CCK4 analogues incorporating IBTM and BTD beta-turn mimetics.
    Martín-Martínez M; De la Figuera N; Latorre M; García-López MT; Cenarruzabeitia E; Del Río J; González-Muñiz R
    J Med Chem; 2005 Dec; 48(24):7667-74. PubMed ID: 16302807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protecting-group-free synthesis of a dual CCK1/CCK2 receptor antagonist.
    Liu J; Deng X; Fitzgerald AE; Sales ZS; Venkatesan H; Mani NS
    Org Biomol Chem; 2011 Apr; 9(8):2654-60. PubMed ID: 21365101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis.
    Latorre M; Bartolomé-Nebreda JM; García-López MT; González-Muñiz R; Herranz R; Del Río J; Cenarruzabeitia E
    Pharmacology; 2004 Oct; 72(2):68-76. PubMed ID: 15331911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
    Morton MF; Barrett TD; Yan W; Freedman JM; Lagaud G; Prendergast CE; Moreno V; Pyati J; Figueroa K; Li L; Wu X; Rizzolio M; Breitenbucher JG; McClure K; Shankley NP
    J Pharmacol Exp Ther; 2007 Nov; 323(2):562-9. PubMed ID: 17684117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy.
    Pippel M; Boyce K; Venkatesan H; Phuong VK; Yan W; Barrett TD; Lagaud G; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6376-8. PubMed ID: 19815410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformationally restricted analogues of the potent CCK-B antagonist CI-988.
    Higginbottom M; Hill DR; Horwell DC; Mostafai E; Suman-Chauhan N; Roberts E
    Bioorg Med Chem; 1993 Sep; 1(3):209-17. PubMed ID: 8081854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.
    van Wijngaarden I; Hamminga D; van Hes R; Standaar PJ; Tipker J; Tulp MT; Mol F; Olivier B; de Jonge A
    J Med Chem; 1993 Nov; 36(23):3693-9. PubMed ID: 8246239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.